Plavix and Liver Function Tests
Introduction to Clopidogrel and LFTs
- The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver suggest that clopidogrel is not specifically listed among medications known to cause significant hepatotoxicity in clinical practice guidelines 1, 2.
- The National Comprehensive Cancer Network notes that unlike many other medications that have documented associations with elevated LFTs, clopidogrel does not appear in tables of drugs with known hepatotoxic effects 3, 4.
Evaluation and Management of Elevated LFTs
- When evaluating elevated LFTs in patients on clopidogrel, the American College of Gastroenterology recommends ruling out other more common causes of LFT elevation before attributing it to clopidogrel, such as viral hepatitis, alcohol consumption, other medications with known hepatotoxicity, underlying liver disease, and biliary obstruction 1, 4, 5.
- The British Society for Clinical Pharmacology suggests considering the temporal relationship between drug initiation and LFT elevation, assessing the pattern of liver injury, and evaluating for presence of systemic symptoms suggesting drug hypersensitivity when evaluating elevated LFTs in patients on multiple medications 2, 5.
- For patients with moderate to severe LFT elevations while on clopidogrel, the American Society of Clinical Oncology recommends considering temporary discontinuation of clopidogrel if clinically feasible, performing a thorough evaluation for other causes of liver injury, and monitoring LFTs after discontinuation to assess for improvement 1, 5.
Special Patient Populations
- In patients with pre-existing liver disease, the American Association for the Study of Liver Diseases recommends regular monitoring of LFTs as a precaution, as clopidogrel may be a safer choice compared to medications with known hepatotoxic effects 5.
- For patients requiring antiplatelet therapy who develop significant LFT abnormalities on clopidogrel, the European Society of Cardiology suggests considering alternative antiplatelet agents after consulting with cardiology, and evaluating the risk-benefit ratio of continuing therapy versus switching agents 2.